NCT05441267Active, not recruitingPhase 4
A Study of Cardiovascular Events iN Diabetes Plus
Source: ClinicalTrials.gov · Last updated 23 Jun 2026
Brief summary (registry, in English)
ASCEND PLUS is testing whether, for people with type 2 diabetes who have not previously had a heart attack or stroke, regularly taking a tablet called semaglutide can safely help to reduce heart attacks, strokes, mini-strokes, the need for any procedures to unblock or bypass an artery to their heart, and the chance of dying because of vascular problems.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 21296 (actual)
- First submitted
- 27 Jun 2022
- Start date
- 13 Mar 2023
- Primary completion date
- 17 Aug 2028
- Lead sponsor
- University of Oxford
- Diseases
- Type 2 diabetes
- NCT number
- NCT05441267
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 21296
- From 13 Mar 2023 to the primary completion date, 17 Aug 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current or planned treatment with a GLP-1 RA
- Previous hypersensitivity to or intolerance of GLP-1 RA therapy
- Current or planned renal replacement therapy
Other illness
- Myocardial Infarction
- Stroke
- Severe heart failure (NYHA class 4)
- Ongoing treatment for cancer or diagnosis with cancer (excluding non-melanoma skin cancer) in the last 2 years
- Type 1 or other type of diabetes (e.g. MODY)
- History of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma
- Any serious illness which is likely to limit survival or active participation for at least 5 years
- Current participation in a clinical trial with an unlicensed investigational medicinal product used to treat diabetes
Other
- Severe hypoglycaemia within the last six months or during run-in
- Symptomatic hypoglycaemia within the last month
- Currently under consideration to commence insulin
- Unwilling to complete regular follow-up assessments
- Currently breastfeeding or pregnant, or planning a pregnancy
- For participants taking thyroxine, lack of agreement to arrange a thyroid function test in the next 3 months and agree to regular testing throughout the trial
- Non-adherence to run-in treatment (i.e. reports taking the run-in tablets 'Never' or 'Only occasionally')
- Their doctor does not wish them to be randomised
Who the study is looking for
- Adults aged at least 55 years at the time of the Screening assessment
- Type 2 Diabetes Mellitus (based on self-reported medical history)
Age in the registry: 55 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clinical Trial Service Unit and Epidemiological Studies Unit Coordinator of this site? Confirm its status | Oxford | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.